Literature DB >> 20125170

Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA?

Yvonne P M Goekoop-Ruiterman1, Tom W J Huizinga.   

Abstract

Since the introduction of new biologic agents and intensive treatment strategies that aim to tightly control disease activity, clinical remission has become a realistic target in patients with rheumatoid arthritis. Once patients are in continuous remission, however, is it realistic to consider withdrawing DMARD therapy?

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20125170     DOI： 10.1038/nrrheum.2009.253

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  9 in total

1.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 2.  Treatment of rheumatoid arthritis: state of the art 2009.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

3.  Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.

Authors:  T Tiippana-Kinnunen; L Paimela; H Kautiainen; L Laasonen; M Leirisalo-Repo
Journal:  Scand J Rheumatol       Date:  2010       Impact factor: 3.641

Review 4.  Optimizing treatment with biologics.

Authors:  Reuven Mader; Edward Keystone
Journal:  J Rheumatol Suppl       Date:  2007-11

5.  Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

Authors:  S M van der Kooij; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; M Güler-Yüksel; A H Zwinderman; P J S M Kerstens; P A H M van der Lubbe; W M de Beus; B A M Grillet; H K Ronday; T W J Huizinga; F C Breedveld; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2008-07-28       Impact factor: 19.103

6.  Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.

Authors:  Diane van der Woude; Adam Young; Keeranur Jayakumar; Bart J Mertens; René E M Toes; Désirée van der Heijde; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2009-08

7.  Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.

Authors:  S ten Wolde; F C Breedveld; J Hermans; J P Vandenbroucke; M A van de Laar; H M Markusse; M Janssen; H R van den Brink; B A Dijkmans
Journal:  Lancet       Date:  1996-02-10       Impact factor: 79.321

8.  Preliminary criteria for clinical remission in rheumatoid arthritis.

Authors:  R S Pinals; A T Masi; R A Larsen
Journal:  Arthritis Rheum       Date:  1981-10

Review 9.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.

Authors:  M F Bakker; J W G Jacobs; S M M Verstappen; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 27.973
  9 in total
  12 in total

1.  The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium.

Authors:  Guoning Guo; Yongjun Shang; Guoyan Zhu; Xiaoren Bao; Shiwei Xu; Yongwen Chen
Journal:  Clin Rheumatol       Date:  2011-07-22       Impact factor: 2.980

Review 2.  Unresolved issues in biologic therapy for rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2011-03-08       Impact factor: 20.543

Review 3.  Remission in rheumatoid arthritis.

Authors:  Rania M Shammas; Veena K Ranganath; Harold E Paulus
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

4.  The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.

Authors:  Yongjun Shang; Guoning Guo; Qifu Cui; Jinlong Li; Zhihua Ruan; Yongwen Chen
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

5.  lncRNA expression profiles related to apoptosis and autophagy in peripheral blood mononuclear cells of patients with rheumatoid arthritis.

Authors:  Jianting Wen; Jian Liu; Hui Jiang; Lei Wan; Ling Xin; Yue Sun; Pingheng Zhang; Yanqiu Sun; Ying Zhang; Xinlei Du; Xin Wang; Jie Wang
Journal:  FEBS Open Bio       Date:  2020-07-22       Impact factor: 2.693

6.  Identification of circular RNAs hsa_circ_0044235 in peripheral blood as novel biomarkers for rheumatoid arthritis.

Authors:  Q Luo; L Zhang; X Li; B Fu; Z Deng; C Qing; R Su; J Xu; Y Guo; Z Huang; J Li
Journal:  Clin Exp Immunol       Date:  2018-09-23       Impact factor: 4.330

7.  In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics.

Authors:  Zhenzhen Ma; Cheng Tao; Lin Sun; Shengbei Qi; Yuan Le; Jiexin Wang; Changhong Li; Xiangyuan Liu; Jianjun Zhang; Jinxia Zhao
Journal:  Int J Nanomedicine       Date:  2019-11-06

8.  Circular RNAs Hsa_circ_0002715 and Hsa_circ_0035197 in Peripheral Blood Are Novel Potential Biomarkers for New-Onset Rheumatoid Arthritis.

Authors:  Qing Luo; Jun Liu; Biqi Fu; Lu Zhang; Yang Guo; Zikun Huang; Junming Li
Journal:  Dis Markers       Date:  2019-10-29       Impact factor: 3.434

9.  Elevated Expression of Immunoreceptor Tyrosine-Based Inhibitory Motif (TIGIT) on T Lymphocytes is Correlated with Disease Activity in Rheumatoid Arthritis.

Authors:  Qing Luo; Zhen Deng; Chuxin Xu; Lulu Zeng; Jianqing Ye; Xue Li; Yang Guo; Zikun Huang; Junming Li
Journal:  Med Sci Monit       Date:  2017-03-10

10.  TIPE2 expression is increased in peripheral blood mononuclear cells from patients with rheumatoid arthritis.

Authors:  Zhu Shi-Bai; Liu Rui-Min; Sun Ying-Chuan; Zhai Jie; Jiang Chao; Ye Can-Hua; Chen Xi; Qian Wen-Wei
Journal:  Oncotarget       Date:  2017-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.